Issue 19

The PSYCH Virtual Investor Summit: Europe & Asia will connect a qualified investor community in Europe and Asia with the leaders from the most innovative and exciting businesses operating in the global psychedelic industry.

BUSINESS AND INVESTMENT


ATAI announces raise of US$157m and US$2b valuation in venture fundraising round.


Awakn acquires next-generation MDMA and ketamine research data from Prof. David Nutt.


Lobe Sciences completes previously announced sale of cannabis assets to Ionic Brands.


Founder of Apeiron Investment Group pens open letter on importance of patient-first approach in psychedelics.


MindMed closes financing of C$19.5m and raises cash holding to C$205.2m.


The race to patent psychedelics predicted to increase significantly.


Defiance ETFs group files with the SEC to launch Defiance NextGen Altered Experience ETF.


ATMA Journey Centers announces Costa Rican expansion.


Numinas placed at the forefront of global psychedelics research after regulatory approvals.


Silo Wellness opens second ketamine-assisted psychedelic wellness retreat.


Psyence Group announces partnership with Base Pair Health and strengthens management team.


Silo Wellness commences trading on the Canadian Securities Exchange.


Revive Therapeutics is advancing its psilocybin programme after acquiring PharmaTher.


Optimi Health accelerates psilocybin clinical trial.

RESULTS OF GLOBAL DRUG SURVEY PUBLISHED

According to the results of the 2020 Global Drug Survey, women are more likely than men to use LSD and psilocybin to treat psychiatric conditions and emotional distress while it has also been found that psychedelics are most commonly used to alleviate depression, anxiety, and difficulties arising from relationship problems.

RESEARCH & SCIENCE


Process of how psilocybin reduces symptoms of depression revealed.


Study finds ketamine can help patients manage depression and PTSD.


Successful medical applications of psilocybin help erode harmful stigmas.


Speech analytics may help researchers evaluate the effectiveness of psychedelic therapy.


The effects of antidepressant discontinuation on MDMA-assisted psychotherapy.


Can psilocybin and LSD relieve existential suffering?

HOW MICRODOSING AND THE PLACEBO EFFECT MIRROR ONE ANOTHER

Following the publication of results that show that the placebo effect can mirror that of microdosing psychedelics, enjoy access to a full panel discussion between a number of leading researchers involved in designing and carrying out similar clinical studies.

REGULATION & LEGISLATION


Veterans groups tell Congress they want access to cannabis and psychedelics.


Greens’ MP hopes Canberra will be the first to introduce psychedelic-assisted therapy.


Local activists in Washington State push for psilocybin decriminalisation.


Legal challenge to allow psilocybin therapy in end-of-life care under ‘Right-to-try’ laws moves forward.


New York lawmaker files bill to decriminalise psilocybin.